Dr. Garland set out the Company's principal goals for 2009 as follows: "We will conduct additional IND-enabling preclinical studies with AGX51 and present findings from these studies at a major cancer meeting in 2009. The new studies will include expanded safety and additional anti-tumor testing of AGX51 in animals as well as further exploration of the feasibility of use of our companion diagnostic for theranostic purposes. Our goal is to file an IND on AGX51 and to initiate human testing within the next twelve to eighteen months. AngioGenex also plans to recruit at least one new Board member who can help guide the Company's effort to raise additional capital and move its program forward. Raising capital to fund our drug development work will continue to be a central focus of effort in 2009."
AngioGenex, Inc. is actively engaged in the discovery, acquisition and development of anti-cancer molecules that act by inhibiting either the Id genes or proteins to prevent the formation of new blood vessels into tumors (angiogenesis). The Company's technology is based on the research of Dr. Robert Benezra and his colleagues at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City who established that activation of the Id genes is required for the formation of new blood vessels into tumors, allowing tumors to grow and metastasize. Dr. Benezra demonstrated that the absence of the Id genes in animals results in a highly significant inhibition of tumor growth and a reduction in the size of mature tumors. The research of Dr. Benezra on the role of the Id genes in tumor formation has been widely recognized for its important therapeutic implications.
This press release may contain forward-looking statements that involve risks and uncertainties that could cause actual events or results to diffe
SOURCE AngioGenex, Inc.
Copyright©2008 PR Newswire.
All rights reserved